State of Alaska Department of Revenue Has $2.35 Million Holdings in Glaukos Corporation $GKOS

State of Alaska Department of Revenue lessened its position in Glaukos Corporation (NYSE:GKOS) by 15.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,854 shares of the medical instruments supplier’s stock after selling 5,167 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.05% of Glaukos worth $2,353,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Park Place Capital Corp lifted its holdings in shares of Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 162 shares in the last quarter. AlphaQuest LLC raised its position in Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 633 shares during the period. Smartleaf Asset Management LLC lifted its stake in Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Glaukos by 909.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock worth $129,000 after acquiring an additional 1,128 shares during the period. Finally, M&T Bank Corp acquired a new stake in Glaukos during the 2nd quarter worth about $203,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on GKOS shares. Truist Financial upped their target price on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. Stifel Nicolaus set a $115.00 target price on shares of Glaukos in a research report on Monday, October 27th. Piper Sandler restated an “overweight” rating and set a $165.00 price target on shares of Glaukos in a report on Wednesday. Finally, Stephens upped their price target on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 2nd. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average price target of $127.92.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Needham & Company reaffirmed a “buy” rating and set a $125 price target on GKOS, implying meaningful upside versus current levels, which can support the stock. Benzinga: Needham Reaffirm Buy
• Positive Sentiment: Glaukos reported preliminary, unaudited fourth-quarter net sales and reaffirmed its full-year 2026 revenue guidance — the top-line beat in the preliminary release is a constructive sign for underlying demand. Business Wire: Preliminary Q4 Sales & 2026 Guidance
• Neutral Sentiment: Glaukos presented at the 44th Annual J.P. Morgan Healthcare Conference; the transcript is available for investors parsing product timelines, adoption cadence and management commentary. Seeking Alpha: JPM Conference Transcript
• Neutral Sentiment: Glaukos updated its Q4 2025, FY2025 and FY2026 EPS guidance in recent filings/updates, but the entries referenced here did not include specific EPS figures, leaving earnings expectations unclear and increasing short-term uncertainty for investors.
• Negative Sentiment: Despite the preliminary top-line beat, headlines and company commentary indicating a disappointing sales forecast specifically for the iDose implant triggered a sell-off and heavy volume as investors worried about growth trajectory for that product line. Investing.com: Stock Falls After Preliminary Q4 Sales Beat MarketWatch: iDose Forecast Disappoints

Insider Activity

In related news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total value of $536,350.00. Following the transaction, the director directly owned 34,905 shares of the company’s stock, valued at approximately $3,744,259.35. This trade represents a 12.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alex R. Thurman sold 315 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the sale, the chief financial officer directly owned 50,488 shares of the company’s stock, valued at $5,301,240. The trade was a 0.62% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 24,655 shares of company stock valued at $2,310,025. Insiders own 5.80% of the company’s stock.

Glaukos Stock Performance

GKOS stock opened at $104.24 on Thursday. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $5.99 billion, a price-to-earnings ratio of -67.69 and a beta of 0.67. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $163.71. The firm has a 50 day moving average of $105.91 and a two-hundred day moving average of $95.34.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. Glaukos’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.28) EPS. As a group, equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.